MedTrace Logo

A Study of r-PA Treating Patients With Acute Ischemic Stroke（RAISE）

NCT05295173 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1412

Last updated 2024-03-04

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy and safety of recombinant human tissue plasminogen kinase derivatives for injection and alteplase in the treatment of patients with acute ischemic stroke within 4.5 hours.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Injection of recombinant human tissue plasminogen kinase derivatives

18mg/10ml/stick, provided by Angde Biotech

DRUG

Recombinant human tissue plasminogen activator

20mg/stick, 50mg/stick, provided by Shanghai Boehringer Ingelheim Pharmaceutical Co. Ltd.

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Angde Biotech Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Yongjun Wang · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2023-06-22
Completion
2023-06-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05295173 on ClinicalTrials.gov